Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)
Binod Dhakal, MD, MS, discusses the management of relapsed multiple myeloma and the various treatment options available.
Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
Maria-Victoria Mateos, MD, PhD, reviews how she manages the side effects of teclistamab, including cytokine release syndrome, in patients with relapsed/refractory multiple myeloma.
Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
Dr Robert Mancini details the bacterial infections usually seen in multiple myeloma patients treated with anti-BCMA bispecific antibodies.
Case 3: A 49-Year-Old with R/R MM Treated with Bispecifics and Develops Adenoviral Infection
An expert panel discusses the case of a 49-year-old with relapsed/refractory multiple myeloma treated with a BCMA bispecific antibody who develops adenoviral infection.
Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
Dr Ajai Chari reviews data from a study looking at the rates of infection in patients with multiple myeloma treated with BCMA-targeting bispecific antibodies, including severe hypogammaglobulinemia.
Mechanism of Action of Teclistamab in R/R MM and Data Updates
Melissa Alsina, MD, explains the mechanism of action, data updates and dosing schedule of the BCMA-targeting bispecific antibody teclistamab.
Clinical Pearls on CRS and ICANS Management in Multiple Myeloma
Moderator Ajai Chari, MD, leads the panel in sharing clinical pearls for management of CRS and ICANS in multiple myeloma before closing out the final module.
Managing Toxicities in Patients With MM Treated with ASCT or Novel Therapies
Michael Scordo, MD, gives an overview of a study on dysgeusia seen in patients with multiple myeloma following autologous stem cell transplant or treatment with novel agents.
The Importance of Access to Care for Multiple Myeloma in Community Settings
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Expanding the Treatment Armamentarium in RRMM with Novel Therapies
Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.
Trials Focused on ctDNA in Colorectal Cancer
An expert panel discusses clinical trials focused on circulating tumor DNA in guiding treatment selection in colorectal cancer.
Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
An overview of the SUNLIGHT and FRESCO-2 studies in the refractory colorectal cancer space.
CARE Clinic Uses Multidisciplinary Approach For Geriatric Multiple Myeloma
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
Using ‘Intensity’ to Gain ‘Deep Control’ in Myeloma at Ohio State
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.
BiTE Therapy May Impact Standard of Care in Multiple Myeloma, Expert Says
Ashley E. Rosko, MD, highlights potential changes on the horizon to the standard of care in multiple myeloma therapy, and discussed the personalization of treatment based on transplant eligibility.
Triplet and Quadruplet Therapy Options for Patients With Transplant-Eligible NDMM
An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.
Future Directions in mHSPC Management: An Evolving Treatment Landscape
Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.
Patient Profile 1: A 61-Year-Old with Transplant-Eligible Newly Diagnosed MM
A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.
MRD Tracking May Allow More ‘Individualized’ Management of Multiple Myeloma
C. Ola Landgren, MD, PhD, illustrated how minimal residual disease tracking may allow greater treatment personalization in the future.
